Clovis Oncology

Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Their development programs are targeted at specific subsets of cancer, combining precision medicine with companion diagnostics to direct therapeutics to those patients most likely to benefit from them.

Clovis Oncology recently reported their Q2 earnings with a miss on EPS and revenue. This was followed by a chain of bad news that made CLVS into a "falling knife."

Clovis Oncology: I Decided To Catch The Falling Knife

President and CEO of Clovis Oncology Inc (30-Year Financial, Insider Trades) Patrick J Mahaffy (insider trades) bought 50,000 shares of CLVS on 08/16/2019 at an average price of $5.59 a share.

Clovis Oncology Inc (CLVS) President and CEO Patrick J Mahaffy Bought $279,500 of Shares

Axon Enterprise

Exxon Mobil

If you are looking for stocks that offer investors value in an overpriced market, take a gander at this diverse trio.

3 Stocks That Are Absurdly Cheap Right Now: AAXN, CLVS & XOM

Clovis (CLVS) reports dismal second-quarter 2019 results. The company provides lower-than-expected guidance for product sales in 2019.

Clovis (CLVS) Q2 Earnings & Sales Lag Estimates, Shares Down

Clovis Oncology, Inc. (CLVS) CEO Patrick Mahaffy on Q2 2019 Results - Earnings Call Transcript

The company reported a net loss of $120 million for the second quarter, which was much worse than analysts expected.

Here's Why Clovis Oncology Stock Fell as Much as 15.6% Today

Investors need to pay close attention to Clovis (CLVS) stock based on the movements in the options market lately.

Do Options Traders Know Something About Clovis (CLVS) Stock We Don't?

Clovis (CLVS) reported earnings 30 days ago. What's next for the stock?

Why Is Clovis (CLVS) Down 25.3% Since Last Earnings Report?

Esperion Therapeutics

Clovis Oncology and Esperion Therapeutics stocks skidded Wednesday after an analyst downgraded the biotech companies to sell ratings amid rising competition in their respective markets.

Biotech Stocks Clobbered As Two Slammed With Sell Ratings

Clovis (CLVS) reports encouraging first-quarter 2019 results. Rubraca maintains market share during the quarter.

Clovis (CLVS) Q1 Earnings Top Estimates, Rubraca Sales Strong

Clovis Oncology, Inc. (CLVS) CEO Patrick Mahaffy on Q1 2019 Results - Earnings Call Transcript

Clovis Oncology had to discontinue its phase 2 open-label study using rucaparib to treat patients with recurrent, metastatic bladder cancer.

Clovis Oncology Suffers Setback, But Additional Options Remain

Although sales of Clovis' (CLVS) Rubraca improved in the fourth quarter of 2018, the drug may face significant competition going forward. Clovis is also evaluating Rubrca for other cancer indications.

Clovis Focuses on Rubraca Label Expansion, Competition Stiff

The company decided to discontinue an important clinical trial.

Here's Why Clovis Oncology Stock Dropped as Much as 13% Today

Clovis Oncology Inc. shares dropped on Monday after the firm announced that it would be halting its midstage trial testing its lead drug in bladder cancer patients.

Why Clovis Bladder Cancer Treatment Rucaparib Is in Big Trouble

Clovis Oncology (CLVS) halts mid-stage bladder cancer study evaluating Rubraca monotherapy. It is unlikely to provide meaningful clinical benefit as reviewed by an independent data monitoring committee.

Clovis Stalls Mid-Stage Rubraca Study for Bladder Cancer

Clovis Oncology Inc. stock tumbled more than 14% in after-hours trading Friday.

Clovis Oncology stock tumbles after company halts bladder-cancer-treatment trial: report

Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

News for Clovis Oncology Stock (CLVS)